Role of vasoactive intestinal peptide (VIP) in pathogenesis of ethanol-induced gastric mucosal damage in rats.

Karmeli F, Eliakim R, Okon E, Rachmilewitz D

Digestive diseases and sciences1 Jul 1993Cited by 4 (Europe PMC)

PMID7686841DOI10.1007/bf01296069PepBankPUB-07686841

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In rats given intragastric ethanol, coadministered VIP doubled the mean gastric lesion area compared with ethanol alone.
In plain wordsIn rats, VIP given with ethanol doubled the stomach damage compared with ethanol alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseEthanol-induced gastric lesion area
Study
ratn: not reported in source
rats with ethanol-induced gastric mucosal damage
Comparator
Ethanol alone
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
1 nmol/liter to 1 mumol/liter/100 g · intravenous or intraperitoneal coadministration with intragastric ethanolAs given in this study (rat).
Source sentences
Summary
VIP was found to double the mean lesion area when compared with that induced by ethanol alone (P < 0.05), an effect that was prevented by VIP antagonist (1 mumol/liter/100 g).
1 context sentence(design, population, supporting numbers)
Summary · context
To elucidate the possible role of vasoactive intestinal peptide (VIP) in the pathogenesis of acute gastric mucosal damage, rats were treated intragastrically with 1.0 ml 96% ethanol with or without intravenous or intraperitoneal coadministration of VIP (1 nmol/liter to 1 mumol/liter/100 g).
Report a problemFND-0768684101
02AnimalAnimal study (in vivo)Mechanism
In rats, the increase in ethanol-induced gastric damage by VIP was associated with higher gastric mucosal LTB4 levels.
In plain wordsIn rats, the added stomach damage from VIP with ethanol went together with higher LTB4 levels in the stomach lining.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseGastric mucosal LTB4 level with VIP and ethanol
Study
ratn: not reported in source
rats with ethanol-induced gastric mucosal damage
Outcome group
Inflammation markers · Gastrointestinal
Studied dose
1 nmol/liter to 1 mumol/liter/100 g · intravenous or intraperitoneal coadministration with intragastric ethanolAs given in this study (rat).
Source sentences
Summary
The augmentation of ethanol-induced damage by VIP was associated with increased gastric mucosal levels of LTB4.
Report a problemFND-0768684103
03AnimalAnimal study (in vivo)Mechanism
In VIP-treated rats, gastric mucosal substance P levels were significantly higher than in control rats.
In plain wordsIn rats, VIP treatment raised substance P levels in the stomach lining compared with control rats.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseGastric mucosal substance P level after VIP
Study
ratn: not reported in source
rats with ethanol-induced gastric mucosal damage
Comparator
Control rats
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
In VIP-treated rats, gastric mucosal levels of substance P were found to be significantly increased compared with control rats (P < 0.05).
Report a problemFND-0768684104
04AnimalAnimal study (in vivo)Efficacy outcome
In pyloric-ligated rats, VIP significantly increased gastric acid output compared with saline.
In plain wordsIn rats, VIP increased stomach acid output compared with saline.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseGastric acid output in pyloric-ligated rats
Study
ratn: not reported in source
pyloric-ligated rats
Comparator
Saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Administration of VIP to pyloric-ligated rats significantly increased gastric acid output and blood pepsinogen A levels as compared with saline treated rats (P < 0.05).
Report a problemFND-0768684105
05AnimalAnimal study (in vivo)Efficacy outcome
In pyloric-ligated rats, VIP significantly increased blood pepsinogen A levels compared with saline.
In plain wordsIn rats, VIP raised blood pepsinogen A levels compared with saline.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBlood pepsinogen A level in pyloric-ligated rats
Study
ratn: not reported in source
pyloric-ligated rats
Comparator
Saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Administration of VIP to pyloric-ligated rats significantly increased gastric acid output and blood pepsinogen A levels as compared with saline treated rats (P < 0.05).
Report a problemFND-0768684106

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

06AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, ethanol treatment significantly increased gastric mucosal VIP levels compared with saline treatment.
In plain wordsIn rats, ethanol raised the body's own VIP level in the stomach lining compared with saline.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseGastric mucosal VIP level after ethanol
Study
ratn: not reported in source
rats with ethanol-induced gastric mucosal damage
Comparator
Saline-treated rats
Outcome group
Endogenous peptide levels · Gastrointestinal
Source sentences
Summary
Gastric mucosal levels of LTB4, LTC4, VIP, and substance P were significantly increased in ethanol-treated rats as compared with saline-treated animals (P < 0.05).
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0768684102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.